214 related articles for article (PubMed ID: 35317422)
1. Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment.
Gokcen P; Guzelbulut F; Adali G; Degirmenci Salturk AG; Ozturk O; Bahadir O; Kanatsiz E; Kiyak M; Ozdil K; Doganay HL
World J Gastroenterol; 2022 Feb; 28(6):665-674. PubMed ID: 35317422
[TBL] [Abstract][Full Text] [Related]
2. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
Kim JH; Kim YD; Lee M; Jun BG; Kim TS; Suk KT; Kang SH; Kim MY; Cheon GJ; Kim DJ; Baik SK; Choi DH
J Hepatol; 2018 Nov; 69(5):1066-1073. PubMed ID: 30075230
[TBL] [Abstract][Full Text] [Related]
3. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
[TBL] [Abstract][Full Text] [Related]
4. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy.
Güzelbulut F; Gökçen P; Can G; Adalı G; Değirmenci Saltürk AG; Bahadır Ö; Özdil K; Doğanay HL
J Viral Hepat; 2021 May; 28(5):826-836. PubMed ID: 33586270
[TBL] [Abstract][Full Text] [Related]
5. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
Chun HS; Papatheodoridis GV; Lee M; Lee HA; Kim YH; Kim SH; Oh YS; Park SJ; Kim J; Lee HA; Kim HY; Kim TH; Yoon EL; Jun DW; Ahn SH; Sypsa V; Yurdaydin C; Lampertico P; Calleja JL; Janssen H; Dalekos GN; Goulis J; Berg T; Buti M; Kim SU; Kim YJ
J Hepatol; 2024 Jan; 80(1):20-30. PubMed ID: 37734683
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
[TBL] [Abstract][Full Text] [Related]
7. Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Kirino S; Tamaki N; Kaneko S; Kurosaki M; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Maeyashiki C; Yasui Y; Nakanishi H; Tsuchiya K; Itakura J; Takahashi Y; Izumi N
J Gastroenterol Hepatol; 2020 Sep; 35(9):1595-1601. PubMed ID: 31975419
[TBL] [Abstract][Full Text] [Related]
8. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
9. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
Papatheodoridis G; Dalekos G; Sypsa V; Yurdaydin C; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Mangia G; Gatselis N; Keskin O; Savvidou S; de la Revilla J; Hansen BE; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
J Hepatol; 2016 Apr; 64(4):800-6. PubMed ID: 26678008
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
Riveiro-Barciela M; Tabernero D; Calleja JL; Lens S; Manzano ML; Rodríguez FG; Crespo J; Piqueras B; Pascasio JM; Comas C; Gutierrez ML; Aguirre A; Suárez E; García-Samaniego J; Rivero M; Acero D; Fernandez-Bermejo M; Moreno D; Sánchez-Pobre P; de Cuenca B; Moreno-Palomares JJ; Esteban R; Buti M
Dig Dis Sci; 2017 Mar; 62(3):784-793. PubMed ID: 28078526
[TBL] [Abstract][Full Text] [Related]
11. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir.
Chang JW; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Seo YS; Lee HA; Kim MN; Lee YR; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Park SY; Kim SU
J Viral Hepat; 2021 Jan; 28(1):95-104. PubMed ID: 33029863
[TBL] [Abstract][Full Text] [Related]
12. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
[TBL] [Abstract][Full Text] [Related]
13. Diabetes Mellitus Impacts on the Performance of Hepatocellular Carcinoma Risk Scores in Chronic Hepatitis B Patients.
Yip TC; Wong VW; Lai MS; Lai JC; Tse YK; Liang LY; Hui VW; Chan HL; Wong GL
Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2864-2875.e16. PubMed ID: 36828301
[TBL] [Abstract][Full Text] [Related]
14. External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China.
Lou T; Li B; Xiong P; Jin C; Chen Y
J Viral Hepat; 2021 Oct; 28(10):1373-1380. PubMed ID: 34218498
[TBL] [Abstract][Full Text] [Related]
15. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Efficacy of Entecavir and Tenofovir in Reducing Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: A Real-Life Study in Turkey.
Güzelbulut F; Gökçen P; Can G; Adalı G; Değirmenci Saltürk AG; Aslan E; Özdil K; Doğanay HL
Turk J Gastroenterol; 2021 Apr; 32(4):412-421. PubMed ID: 34231488
[TBL] [Abstract][Full Text] [Related]
17. Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B.
Kamalapirat T; Yingcharoen K; Ungtrakul T; Soonklang K; Dechma J; Chunnuan P; Kusuman P; Pothijaroen C; Tawpa J; Cheirsilpa K; Auewarakul C
J Viral Hepat; 2021 Jul; 28(7):1034-1041. PubMed ID: 33880807
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.
Wu X; Xu X; Zhou J; Sun Y; Ding H; Xie W; Chen G; Ma A; Piao H; Wang B; Chen S; Meng T; Ou X; Yang HI; Jia J; Kong Y; You H
Clin Mol Hepatol; 2023 Jul; 29(3):747-762. PubMed ID: 37165622
[TBL] [Abstract][Full Text] [Related]
19. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.
Yu JH; Suh YJ; Jin YJ; Heo NY; Jang JW; You CR; An HY; Lee JW
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):865-872. PubMed ID: 30694912
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
Patmore LA; van Eekhout KMA; Buti M; Koc ÖM; Agarwal K; de Knegt RJ; Janssen HLA; van der Valk M; Lieveld FI; Hansen BE; Kramer M; de Bruijne J; Claassen MAA; Smit C; de Man RA; Takkenberg B; Carey I; Sonneveld MJ;
J Hepatol; 2024 Feb; 80(2):243-250. PubMed ID: 37898348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
